Fresh analysis suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who halt traditional lifestyle plans.
Research printed in a leading medical journal demonstrates that while obese individuals can lose substantial amounts of their total mass while undergoing treatment, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"People buying these medications must be informed of the risk of fast rebound weight gain when the treatment is stopped," cautioned researcher Dr. Susan Jebb.
This pace of regain implies a reversion to original weight within about 18 months.
Comparing Therapies
The analysis, which examined dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
The team emphasize that individuals who shed pounds through dieting generally experience a more gradual creep back—approximately 100 grams monthly—once they finish.
Explaining the Fast Rebound
Nutrition scientists propose the way of the jabs accounts for the amplified weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of GLP-1 levels several times higher than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication results in appetite is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
The NHS recommend the jabs for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, due to the likelihood of relapse, the treatment might need to be long-term.
This view is reinforced by drug manufacturers, who note that the findings "emphasize the chronic nature of obesity," comparing it to managing diseases like diabetes.
Patient Testimonies
People who have stopped the jabs explain a sudden resurgence of hunger.
"It was like a trigger activating and you become extremely hungry," recalled one woman.
The struggle is exacerbated if individuals have not developed permanent lifestyle or habit changes during treatment.
Significant Adoption
Recent estimates show that millions of adults in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Use is more common among women than men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Finally, clinicians emphasize that while these medications are effective tools for shedding pounds, they are not a permanent solution and lasting health benefits relies on combined lifestyle management.
